on Piramal Pharma Solutions
Piramal Pharma Secures Majority Stake in Yapan Bio
Piramal Pharma Limited has completed the acquisition of a controlling 74% stake in Yapan Bio Private Limited for ₹76 crore ($7.95M USD). Yapan Bio, based in Hyderabad, specializes in manufacturing services for vaccines and biologics. This acquisition elevates Yapan from an associate company to a subsidiary within Piramal Pharma Solutions (PPS), enhancing its integrated large molecule CDMO services.
Piramal initially invested in Yapan Bio in 2021, aiming to expand its capabilities in biologics development. The latest transaction aligns with PPL's strategic focus on broadening its presence in the biologics sector. Yapan Bio's expertise will now reinforce PPS's ADCelerate™, a platform for rapid Phase I ADC development.
PPL's acquisition marks a strategic move in its growth plan, integrating Yapan Bio's capabilities to meet global demand for complex biologics. CEO Peter DeYoung emphasized that this investment strengthens their global network and patient-centric approach, streamlining access to essential therapies.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Piramal Pharma Solutions news